Search

Your search keyword '"Wherry, E. John"' showing total 1,370 results
Start Over Author "Wherry, E. John"
1,370 results on '"Wherry, E. John"'

1. Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses

Author

Friedman, Claire F., Manning-Geist, Beryl L., Zhou, Qin, Soumerai, Tara, Holland, Aliya, Da Cruz Paula, Arnaud, Green, Hunter, Ozsoy, Melih Arda, Iasonos, Alexia, Hollmann, Travis, Leitao, Jr., Mario M., Mueller, Jennifer J., Makker, Vicky, Tew, William P., O’Cearbhaill, Roisin E., Liu, Ying L., Rubinstein, Maria M., Troso-Sandoval, Tiffany, Lichtman, Stuart M., Schram, Alison, Kyi, Chrisann, Grisham, Rachel N., Causa Andrieu, Pamela, Wherry, E. John, Aghajanian, Carol, Weigelt, Britta, Hensley, Martee L., and Zamarin, Dmitriy

Published
2024
Full Text
View/download PDF

2. Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial

Author

Bagley, Stephen J., Binder, Zev A., Lamrani, Lamia, Marinari, Eliana, Desai, Arati S., Nasrallah, MacLean P., Maloney, Eileen, Brem, Steven, Lustig, Robert A., Kurtz, Goldie, Alonso-Basanta, Michelle, Bonté, Pierre-Emmanuel, Goudot, Christel, Richer, Wilfrid, Piaggio, Eliane, Kothari, Shawn, Guyonnet, Lea, Guerin, Coralie L., Waterfall, Joshua J., Mohan, Suyash, Hwang, Wei-Ting, Tang, Oliver Y., Logun, Meghan, Bhattacharyya, Meghna, Markowitz, Kelly, Delman, Devora, Marshall, Amy, Wherry, E. John, Amigorena, Sebastian, Beatty, Gregory L., Brogdon, Jennifer L., Hexner, Elizabeth, Migliorini, Denis, Alanio, Cecile, and O’Rourke, Donald M.

Published
2024
Full Text
View/download PDF

4. SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC)

Author

Proal, Amy D., VanElzakker, Michael B., Aleman, Soo, Bach, Katie, Boribong, Brittany P., Buggert, Marcus, Cherry, Sara, Chertow, Daniel S., Davies, Helen E., Dupont, Christopher L., Deeks, Steven G., Eimer, William, Ely, E. Wesley, Fasano, Alessio, Freire, Marcelo, Geng, Linda N., Griffin, Diane E., Henrich, Timothy J., Iwasaki, Akiko, Izquierdo-Garcia, David, Locci, Michela, Mehandru, Saurabh, Painter, Mark M., Peluso, Michael J., Pretorius, Etheresia, Price, David A., Putrino, David, Scheuermann, Richard H., Tan, Gene S., Tanzi, Rudolph E., VanBrocklin, Henry F., Yonker, Lael M., and Wherry, E. John

Published
2023
Full Text
View/download PDF

5. Prior vaccination promotes early activation of memory T cells and enhances immune responses during SARS-CoV-2 breakthrough infection

Author

Painter, Mark M., Johnston, Timothy S., Lundgreen, Kendall A., Santos, Jefferson J. S., Qin, Juliana S., Goel, Rishi R., Apostolidis, Sokratis A., Mathew, Divij, Fulmer, Bria, Williams, Justine C., McKeague, Michelle L., Pattekar, Ajinkya, Goode, Ahmad, Nasta, Sean, Baxter, Amy E., Giles, Josephine R., Skelly, Ashwin N., Felley, Laura E., McLaughlin, Maura, Weaver, Joellen, Kuthuru, Oliva, Dougherty, Jeanette, Adamski, Sharon, Long, Sherea, Kee, Macy, Clendenin, Cynthia, da Silva Antunes, Ricardo, Grifoni, Alba, Weiskopf, Daniela, Sette, Alessandro, Huang, Alexander C., Rader, Daniel J., Hensley, Scott E., Bates, Paul, Greenplate, Allison R., and Wherry, E. John

Published
2023
Full Text
View/download PDF

6. LAG-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity

Author

Ngiow, Shin Foong, Manne, Sasikanth, Huang, Yinghui Jane, Azar, Tarek, Chen, Zeyu, Mathew, Divij, Chen, Qingzhou, Khan, Omar, Wu, Jennifer E., Alcalde, Victor, Flowers, Ahron J., McClain, Sean, Baxter, Amy E., Kurachi, Makoto, Shi, Junwei, Huang, Alexander C., Giles, Josephine R., Sharpe, Arlene H., Vignali, Dario A.A., and Wherry, E. John

Published
2024
Full Text
View/download PDF

7. LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunity

Author

Andrews, Lawrence P., Butler, Samuel C., Cui, Jian, Cillo, Anthony R., Cardello, Carly, Liu, Chang, Brunazzi, Erin A., Baessler, Andrew, Xie, Bingxian, Kunning, Sheryl R., Ngiow, Shin Foong, Huang, Yinghui Jane, Manne, Sasikanth, Sharpe, Arlene H., Delgoffe, Greg M., Wherry, E. John, Kirkwood, John M., Bruno, Tullia C., Workman, Creg J., and Vignali, Dario A.A.

Published
2024
Full Text
View/download PDF

8. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial

Author

Padrón, Lacey J, Maurer, Deena M, O’Hara, Mark H, O’Reilly, Eileen M, Wolff, Robert A, Wainberg, Zev A, Ko, Andrew H, Fisher, George, Rahma, Osama, Lyman, Jaclyn P, Cabanski, Christopher R, Yu, Jia Xin, Pfeiffer, Shannon M, Spasic, Marko, Xu, Jingying, Gherardini, Pier Federico, Karakunnel, Joyson, Mick, Rosemarie, Alanio, Cécile, Byrne, Katelyn T, Hollmann, Travis J, Moore, Jonni S, Jones, Derek D, Tognetti, Marco, Chen, Richard O, Yang, Xiaodong, Salvador, Lisa, Wherry, E John, Dugan, Ute, O’Donnell-Tormey, Jill, Butterfield, Lisa H, Hubbard-Lucey, Vanessa M, Ibrahim, Ramy, Fairchild, Justin, Bucktrout, Samantha, LaVallee, Theresa M, and Vonderheide, Robert H

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Pancreatic Cancer, Clinical Trials and Supportive Activities, Cancer, Orphan Drug, Clinical Research, Rare Diseases, Digestive Diseases, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Albumins, Antibodies, Monoclonal, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Pancreatic Ductal, Humans, Nivolumab, Pancreatic Neoplasms, Tumor Microenvironment, Medical and Health Sciences, Biomedical and clinical sciences, Health sciences
Abstract

Chemotherapy combined with immunotherapy has improved the treatment of certain solid tumors, but effective regimens remain elusive for pancreatic ductal adenocarcinoma (PDAC). We conducted a randomized phase 2 trial evaluating the efficacy of nivolumab (nivo; anti-PD-1) and/or sotigalimab (sotiga; CD40 agonistic antibody) with gemcitabine/nab-paclitaxel (chemotherapy) in patients with first-line metastatic PDAC ( NCT03214250 ). In 105 patients analyzed for efficacy, the primary endpoint of 1-year overall survival (OS) was met for nivo/chemo (57.7%, P = 0.006 compared to historical 1-year OS of 35%, n = 34) but was not met for sotiga/chemo (48.1%, P = 0.062, n = 36) or sotiga/nivo/chemo (41.3%, P = 0.223, n = 35). Secondary endpoints were progression-free survival, objective response rate, disease control rate, duration of response and safety. Treatment-related adverse event rates were similar across arms. Multi-omic circulating and tumor biomarker analyses identified distinct immune signatures associated with survival for nivo/chemo and sotiga/chemo. Survival after nivo/chemo correlated with a less suppressive tumor microenvironment and higher numbers of activated, antigen-experienced circulating T cells at baseline. Survival after sotiga/chemo correlated with greater intratumoral CD4 T cell infiltration and circulating differentiated CD4 T cells and antigen-presenting cells. A patient subset benefitting from sotiga/nivo/chemo was not identified. Collectively, these analyses suggest potential treatment-specific correlates of efficacy and may enable biomarker-selected patient populations in subsequent PDAC chemoimmunotherapy trials.

Published
2022

9. MicroRNA-29a attenuates CD8 T cell exhaustion and induces memory-like CD8 T cells during chronic infection

Author

Stelekati, Erietta, Cai, Zhangying, Manne, Sasikanth, Chen, Zeyu, Beltra, Jean-Christophe, Buchness, Lance Alec, Leng, Xuebing, Ristin, Svetlana, Nzingha, Kito, Ekshyyan, Viktoriya, Niavi, Christina, Abdel-Hakeem, Mohamed S, Ali, Mohammed-Alkhatim, Drury, Sydney, Lau, Chi Wai, Gao, Zhen, Ban, Yuguang, Zhou, Simon K, Ansel, K Mark, Kurachi, Makoto, Jordan, Martha S, Villarino, Alejandro V, Ngiow, Shin Foong, and Wherry, E John

Subjects
Prevention, Vaccine Related, Emerging Infectious Diseases, Infectious Diseases, Biodefense, Biotechnology, Genetics, 2.1 Biological and endogenous factors, 1.1 Normal biological development and functioning, Underpinning research, Aetiology, Infection, Inflammatory and immune system, CD8-Positive T-Lymphocytes, Humans, Immunotherapy, MicroRNAs, Neoplasms, Persistent Infection, CD8 T cells, microRNA, exhaustion
Abstract

CD8 T cells mediate protection against intracellular pathogens and tumors. However, persistent antigen during chronic infections or cancer leads to T cell exhaustion, suboptimal functionality, and reduced protective capacity. Despite considerable work interrogating the transcriptional regulation of exhausted CD8 T cells (TEX), the posttranscriptional control of TEX remains poorly understood. Here, we interrogated the role of microRNAs (miRs) in CD8 T cells responding to acutely resolved or chronic viral infection and identified miR-29a as a key regulator of TEX. Enforced expression of miR-29a improved CD8 T cell responses during chronic viral infection and antagonized exhaustion. miR-29a inhibited exhaustion-driving transcriptional pathways, including inflammatory and T cell receptor signaling, and regulated ribosomal biogenesis. As a result, miR-29a fostered a memory-like CD8 T cell differentiation state during chronic infection. Thus, we identify miR-29a as a key regulator of TEX and define mechanisms by which miR-29a can divert exhaustion toward a more beneficial memory-like CD8 T cell differentiation state.

Published
2022

13. How Did We Get a COVID-19 Vaccine in Less Than 1 Year?

Author

Wherry, E John, Jaffee, Elizabeth M, Warren, Nicholas, D'Souza, Gypsyamber, Ribas, Antoni, and Force, on behalf of the AACR COVID-19 and Cancer Task

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Immunization, Cancer, Vaccine Related, Prevention, Prevention of disease and conditions, and promotion of well-being, 3.4 Vaccines, Good Health and Well Being, COVID-19, COVID-19 Vaccines, Humans, SARS-CoV-2, Vaccination, AACR COVID-19 and Cancer Task Force, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

The successful development of COVID-19 vaccines within an unprecedented short time needs to be followed by rapid vaccine uptake, in particular, in high-risk populations such as patients with cancer. It is important for the scientific research community and cancer physicians to convey the knowledge behind the COVID-19 vaccine development and contribute to build the required trust on their use.

Published
2021

14. Serotonin reduction in post-acute sequelae of viral infection

Author

Wong, Andrea C., Devason, Ashwarya S., Umana, Iboro C., Cox, Timothy O., Dohnalová, Lenka, Litichevskiy, Lev, Perla, Jonathan, Lundgren, Patrick, Etwebi, Zienab, Izzo, Luke T., Kim, Jihee, Tetlak, Monika, Descamps, Hélène C., Park, Simone L., Wisser, Stephen, McKnight, Aaron D., Pardy, Ryan D., Kim, Junwon, Blank, Niklas, Patel, Shaan, Thum, Katharina, Mason, Sydney, Beltra, Jean-Christophe, Michieletto, Michaël F., Ngiow, Shin Foong, Miller, Brittany M., Liou, Megan J., Madhu, Bhoomi, Dmitrieva-Posocco, Oxana, Huber, Alex S., Hewins, Peter, Petucci, Christopher, Chu, Candice P., Baraniecki-Zwil, Gwen, Giron, Leila B., Baxter, Amy E., Greenplate, Allison R., Kearns, Charlotte, Montone, Kathleen, Litzky, Leslie A., Feldman, Michael, Henao-Mejia, Jorge, Striepen, Boris, Ramage, Holly, Jurado, Kellie A., Wellen, Kathryn E., O’Doherty, Una, Abdel-Mohsen, Mohamed, Landay, Alan L., Keshavarzian, Ali, Henrich, Timothy J., Deeks, Steven G., Peluso, Michael J., Meyer, Nuala J., Wherry, E. John, Abramoff, Benjamin A., Cherry, Sara, Thaiss, Christoph A., and Levy, Maayan

Published
2023
Full Text
View/download PDF

16. Unique challenges for glioblastoma immunotherapy—discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank

Author

Chuntova, Pavlina, Chow, Frances, Watchmaker, Payal B, Galvez, Mildred, Heimberger, Amy B, Newell, Evan W, Diaz, Aaron, DePinho, Ronald A, Li, Ming O, Wherry, E John, Mitchell, Duane, Terabe, Masaki, Wainwright, Derek A, Berzofsky, Jay A, Herold-Mende, Christel, Heath, James R, Lim, Michael, Margolin, Kim A, Chiocca, E Antonio, Kasahara, Noriyuki, Ellingson, Benjamin M, Brown, Christine E, Chen, Yvonne, Fecci, Peter E, Reardon, David A, Dunn, Gavin P, Liau, Linda M, Costello, Joseph F, Wick, Wolfgang, Cloughesy, Timothy, Timmer, William C, Wen, Patrick Y, Prins, Robert M, Platten, Michael, and Okada, Hideho

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Vaccine Related, Brain Cancer, Brain Disorders, Orphan Drug, Cancer, Immunization, Rare Diseases, Neurosciences, Good Health and Well Being, Brain Neoplasms, Glioblastoma, Humans, Immunotherapy, Medical Oncology, Neoplasms, Tumor Microenvironment, clinical trial, conference report, glioblastoma, immunosuppression, immunotherapy, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

Cancer immunotherapy has made remarkable advances with over 50 separate Food and Drug Administration (FDA) approvals as first- or second-line indications since 2015. These include immune checkpoint blocking antibodies, chimeric antigen receptor-transduced T cells, and bispecific T-cell-engaging antibodies. While multiple cancer types now benefit from these immunotherapies, notable exceptions thus far include brain tumors, such as glioblastoma. As such, it seems critical to gain a better understanding of unique mechanistic challenges underlying the resistance of malignant gliomas to immunotherapy, as well as to acquire insights into the development of future strategies. An Immuno-Oncology Think Tank Meeting was held during the 2019 Annual Society for Neuro-Oncology Scientific Conference. Discussants in the fields of neuro-oncology, neurosurgery, neuro-imaging, medical oncology, and cancer immunology participated in the meeting. Sessions focused on topics such as the tumor microenvironment, myeloid cells, T-cell dysfunction, cellular engineering, and translational aspects that are critical and unique challenges inherent with primary brain tumors. In this review, we summarize the discussions and the key messages from the meeting, which may potentially serve as a basis for advancing the field of immune neuro-oncology in a collaborative manner.

Published
2021

17. Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited

Author

Ribas, Antoni, Sengupta, Rajarshi, Locke, Trevan, Zaidi, Sayyed Kaleem, Campbell, Katie M, Carethers, John M, Jaffee, Elizabeth M, Wherry, E John, Soria, Jean-Charles, D'Souza, Gypsyamber, and Force, for the AACR COVID-19 and Cancer Task

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Immunization, Prevention, Rare Diseases, Biotechnology, Emerging Infectious Diseases, Patient Safety, Vaccine Related, Cancer, Prevention of disease and conditions, and promotion of well-being, 3.4 Vaccines, Good Health and Well Being, COVID-19, COVID-19 Vaccines, Health Care Rationing, Hematologic Neoplasms, Humans, Immunity, Immunization Programs, Odds Ratio, Proportional Hazards Models, Public Health, Risk, Risk Factors, Treatment Outcome, Vaccination, AACR COVID-19 and Cancer Task Force, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

Published series on COVID-19 support the notion that patients with cancer are a particularly vulnerable population. There is a confluence of risk factors between cancer and COVID-19, and cancer care and treatments increase exposure to the virus and may dampen natural immune responses. The available evidence supports the conclusion that patients with cancer, in particular with hematologic malignancies, should be considered among the very high-risk groups for priority COVID-19 vaccination.

Published
2021

19. Author Correction: SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC)

Author

Proal, Amy D., VanElzakker, Michael B., Aleman, Soo, Bach, Katie, Boribong, Brittany P., Buggert, Marcus, Cherry, Sara, Chertow, Daniel S., Davies, Helen E., Dupont, Christopher L., Deeks, Steven G., Eimer, William, Ely, E. Wesley, Fasano, Alessio, Freire, Marcelo, Geng, Linda N., Griffin, Diane E., Henrich, Timothy J., Iwasaki, Akiko, Izquierdo-Garcia, David, Locci, Michela, Mehandru, Saurabh, Painter, Mark M., Peluso, Michael J., Pretorius, Etheresia, Price, David A., Putrino, David, Scheuermann, Richard H., Tan, Gene S., Tanzi, Rudolph E., VanBrocklin, Henry F., Yonker, Lael M., and Wherry, E. John

Published
2023
Full Text
View/download PDF

21. Shared and distinct biological circuits in effector, memory and exhausted CD8+ T cells revealed by temporal single-cell transcriptomics and epigenetics

Author

Giles, Josephine R., Ngiow, Shin Foong, Manne, Sasikanth, Baxter, Amy E., Khan, Omar, Wang, Ping, Staupe, Ryan, Abdel-Hakeem, Mohamed S., Huang, Hua, Mathew, Divij, Painter, Mark M., Wu, Jennifer E., Huang, Yinghui Jane, Goel, Rishi R., Yan, Patrick K., Karakousis, Giorgos C., Xu, Xiaowei, Mitchell, Tara C., Huang, Alexander C., and Wherry, E. John

Published
2022
Full Text
View/download PDF

22. The enteric nervous system relays psychological stress to intestinal inflammation

Author

Schneider, Kai Markus, Blank, Niklas, Alvarez, Yelina, Thum, Katharina, Lundgren, Patrick, Litichevskiy, Lev, Sleeman, Madeleine, Bahnsen, Klaas, Kim, Jihee, Kardo, Simon, Patel, Shaan, Dohnalová, Lenka, Uhr, Giulia T., Descamps, Hélène C., Kircher, Susanna, McSween, Alana M., Ardabili, Ashkan Rezazadeh, Nemec, Kelsey M., Jimenez, Monica T., Glotfelty, Lila G., Eisenberg, Joshua D., Furth, Emma E., Henao-Mejia, Jorge, Bennett, F. Chris, Pierik, Marie J., Romberg-Camps, Mariëlle, Mujagic, Zlatan, Prinz, Marco, Schneider, Carolin V., Wherry, E. John, Bewtra, Meenakshi, Heuckeroth, Robert O., Levy, Maayan, and Thaiss, Christoph A.

Published
2023
Full Text
View/download PDF

23. The SWI/SNF chromatin remodeling complexes BAF and PBAF differentially regulate epigenetic transitions in exhausted CD8+ T cells

Author

Baxter, Amy E., Huang, Hua, Giles, Josephine R., Chen, Zeyu, Wu, Jennifer E., Drury, Sydney, Dalton, Katherine, Park, Simone L., Torres, Leonel, Simone, Brandon W., Klapholz, Max, Ngiow, Shin Foong, Freilich, Elizabeth, Manne, Sasikanth, Alcalde, Victor, Ekshyyan, Viktoriya, Berger, Shelley L., Shi, Junwei, Jordan, Martha S., and Wherry, E. John

Published
2023
Full Text
View/download PDF

24. An extended SARS-CoV-2 mRNA vaccine prime-boost interval enhances B cell immunity with limited impact on T cells

Author

Nicolas, Alexandre, Sannier, Gérémy, Dubé, Mathieu, Nayrac, Manon, Tauzin, Alexandra, Painter, Mark M., Goel, Rishi R., Laporte, Mélanie, Gendron-Lepage, Gabrielle, Medjahed, Halima, Williams, Justine C., Brassard, Nathalie, Niessl, Julia, Gokool, Laurie, Morrisseau, Chantal, Arlotto, Pascale, Tremblay, Cécile, Martel-Laferrière, Valérie, Finzi, Andrés, Greenplate, Allison R., Wherry, E. John, and Kaufmann, Daniel E.

Published
2023
Full Text
View/download PDF

26. PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine

Author

Herati, Ramin Sedaghat, Knorr, David A., Vella, Laura A., Silva, Luisa Victoria, Chilukuri, Lakshmi, Apostolidis, Sokratis A., Huang, Alexander C., Muselman, Alexander, Manne, Sasikanth, Kuthuru, Oliva, Staupe, Ryan P., Adamski, Sharon A., Kannan, Senthil, Kurupati, Raj K., Ertl, Hildegund C. J., Wong, Jeffrey L., Bournazos, Stylianos, McGettigan, Suzanne, Schuchter, Lynn M., Kotecha, Ritesh R., Funt, Samuel A., Voss, Martin H., Motzer, Robert J., Lee, Chung-Han, Bajorin, Dean F., Mitchell, Tara C., Ravetch, Jeffrey V., and Wherry, E. John

Published
2022
Full Text
View/download PDF

27. Automated Cytometric Gating with Human-Level Performance Using Bivariate Segmentation

Author

Chen, Jiong, primary, Ionita, Matei, additional, Feng, Yanbo, additional, Lu, Yinfeng, additional, Orzechowski, Patryk, additional, Garai, Sumita, additional, Hassinger, Kenneth, additional, Bao, Jingxuan, additional, Wen, Junhao, additional, Duong-Tran, Duy, additional, Wagenaar, Joost, additional, McKeague, Michelle L., additional, Painter, Mark M., additional, Mathew, Divij, additional, Pattekar, Ajinkya, additional, Meyer, Nuala J., additional, Wherry, E. John, additional, Greenplate, Allison R., additional, and Shen, Li, additional

Published
2024
Full Text
View/download PDF

28. Supplementary Table S3 from FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma

Author

Anderson, Thomas M., primary, Chang, Bryan H., primary, Huang, Alexander C., primary, Xu, Xiaowei, primary, Yoon, Daniel, primary, Shang, Catherine G., primary, Mick, Rosemarie, primary, Schubert, Erin, primary, McGettigan, Suzanne, primary, Kreider, Kristin, primary, Xu, Wei, primary, Wherry, E. John, primary, Schuchter, Lynn M., primary, Amaravadi, Ravi K., primary, Mitchell, Tara C., primary, and Farwell, Michael D., primary

Published
2024
Full Text
View/download PDF

29. Supplementary Figure S2 from FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma

Author

Anderson, Thomas M., primary, Chang, Bryan H., primary, Huang, Alexander C., primary, Xu, Xiaowei, primary, Yoon, Daniel, primary, Shang, Catherine G., primary, Mick, Rosemarie, primary, Schubert, Erin, primary, McGettigan, Suzanne, primary, Kreider, Kristin, primary, Xu, Wei, primary, Wherry, E. John, primary, Schuchter, Lynn M., primary, Amaravadi, Ravi K., primary, Mitchell, Tara C., primary, and Farwell, Michael D., primary

Published
2024
Full Text
View/download PDF

30. Data from FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma

Author

Anderson, Thomas M., primary, Chang, Bryan H., primary, Huang, Alexander C., primary, Xu, Xiaowei, primary, Yoon, Daniel, primary, Shang, Catherine G., primary, Mick, Rosemarie, primary, Schubert, Erin, primary, McGettigan, Suzanne, primary, Kreider, Kristin, primary, Xu, Wei, primary, Wherry, E. John, primary, Schuchter, Lynn M., primary, Amaravadi, Ravi K., primary, Mitchell, Tara C., primary, and Farwell, Michael D., primary

Published
2024
Full Text
View/download PDF

32. A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses

Author

Tauzin, Alexandra, Gong, Shang Yu, Chatterjee, Debashree, Ding, Shilei, Painter, Mark M., Goel, Rishi R., Beaudoin-Bussières, Guillaume, Marchitto, Lorie, Boutin, Marianne, Laumaea, Annemarie, Okeny, James, Gendron-Lepage, Gabrielle, Bourassa, Catherine, Medjahed, Halima, Goyette, Guillaume, Williams, Justine C., Bo, Yuxia, Gokool, Laurie, Morrisseau, Chantal, Arlotto, Pascale, Bazin, Renée, Fafard, Judith, Tremblay, Cécile, Kaufmann, Daniel E., De Serres, Gaston, Richard, Jonathan, Côté, Marceline, Duerr, Ralf, Martel-Laferrière, Valérie, Greenplate, Allison R., Wherry, E. John, and Finzi, Andrés

Published
2022
Full Text
View/download PDF

33. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells

Author

Melenhorst, J. Joseph, Chen, Gregory M., Wang, Meng, Porter, David L., Chen, Changya, Collins, McKensie A., Gao, Peng, Bandyopadhyay, Shovik, Sun, Hongxing, Zhao, Ziran, Lundh, Stefan, Pruteanu-Malinici, Iulian, Nobles, Christopher L., Maji, Sayantan, Frey, Noelle V., Gill, Saar I., Loren, Alison W., Tian, Lifeng, Kulikovskaya, Irina, Gupta, Minnal, Ambrose, David E., Davis, Megan M., Fraietta, Joseph A., Brogdon, Jennifer L., Young, Regina M., Chew, Anne, Levine, Bruce L., Siegel, Donald L., Alanio, Cécile, Wherry, E. John, Bushman, Frederic D., Lacey, Simon F., Tan, Kai, and June, Carl H.

Published
2022
Full Text
View/download PDF

35. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy

Author

Apostolidis, Sokratis A., Kakara, Mihir, Painter, Mark M., Goel, Rishi R., Mathew, Divij, Lenzi, Kerry, Rezk, Ayman, Patterson, Kristina R., Espinoza, Diego A., Kadri, Jessy C., Markowitz, Daniel M., E. Markowitz, Clyde, Mexhitaj, Ina, Jacobs, Dina, Babb, Allison, Betts, Michael R., Prak, Eline T. Luning, Weiskopf, Daniela, Grifoni, Alba, Lundgreen, Kendall A., Gouma, Sigrid, Sette, Alessandro, Bates, Paul, Hensley, Scott E., Greenplate, Allison R., Wherry, E. John, Li, Rui, and Bar-Or, Amit

Published
2021
Full Text
View/download PDF

36. Identification and characterization of HIV-specific resident memory CD8+ T cells in human lymphoid tissue

Author

Buggert, Marcus, Nguyen, Son, Salgado-Montes de Oca, Gonzalo, Bengsch, Bertram, Darko, Samuel, Ransier, Amy, Roberts, Emily R, del Alcazar, Daniel, Brody, Irene Bukh, Vella, Laura A, Beura, Lalit, Wijeyesinghe, Sathi, Herati, Ramin S, Del Rio Estrada, Perla M, Ablanedo-Terrazas, Yuria, Kuri-Cervantes, Leticia, Sada Japp, Alberto, Manne, Sasikanth, Giles, Josephine R, Vartanian, Shant, Huffman, Austin, Sandberg, Johan K, Gostick, Emma, Nadolski, Gregory, Silvestri, Guido, Canaday, David H, Price, David A, Petrovas, Constantinos, Su, Laura F, Vahedi, Golnaz, Dori, Yoav, Frank, Ian, Itkin, Maxim G, Wherry, E John, Deeks, Steven G, Naji, Ali, Reyes-Terán, Gustavo, Masopust, David, Douek, Daniel C, and Betts, Michael R

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Immunology, Genetics, Sexually Transmitted Infections, Immunization, Infectious Diseases, Vaccine Related, HIV/AIDS, 2.1 Biological and endogenous factors, Aetiology, Infection, Good Health and Well Being, Adult, Animals, Antirheumatic Agents, CD8-Positive T-Lymphocytes, Female, HIV Infections, HIV-1, Humans, Immunologic Memory, Lymphoid Tissue, Macaca mulatta, Male, Mice, Mice, Inbred C57BL, Middle Aged, Sequence Analysis, RNA, Single-Cell Analysis, Viral Load, Virus Replication, Young Adult, Clinical sciences
Abstract

Current paradigms of CD8+ T cell-mediated protection in HIV infection center almost exclusively on studies of peripheral blood, which is thought to provide a window into immune activity at the predominant sites of viral replication in lymphoid tissues (LTs). Through extensive comparison of blood, thoracic duct lymph (TDL), and LTs in different species, we show that many LT memory CD8+ T cells bear phenotypic, transcriptional, and epigenetic signatures of resident memory T cells (TRMs). Unlike their circulating counterparts in blood or TDL, most of the total and follicular HIV-specific CD8+ T cells in LTs also resemble TRMs Moreover, high frequencies of HIV-specific CD8+ TRMs with skewed clonotypic profiles relative to matched blood samples are present in LTs of individuals who spontaneously control HIV replication in the absence of antiretroviral therapy (elite controllers). Single-cell RNA sequencing analysis confirmed that HIV-specific TRMs are enriched for effector-related immune genes and signatures compared with HIV-specific non-TRMs in elite controllers. Together, these data indicate that previous studies in blood have largely failed to capture the major component of HIV-specific CD8+ T cell responses resident within LTs.

Published
2018

37. Limited immune surveillance in lymphoid tissue by cytolytic CD4+ T cells during health and HIV disease.

Author

Buggert, Marcus, Nguyen, Son, McLane, Laura M, Steblyanko, Maria, Anikeeva, Nadia, Paquin-Proulx, Dominic, Del Rio Estrada, Perla M, Ablanedo-Terrazas, Yuria, Noyan, Kajsa, Reuter, Morgan A, Demers, Korey, Sandberg, Johan K, Eller, Michael A, Streeck, Hendrik, Jansson, Marianne, Nowak, Piotr, Sönnerborg, Anders, Canaday, David H, Naji, Ali, Wherry, E John, Robb, Merlin L, Deeks, Steven G, Reyes-Teran, Gustavo, Sykulev, Yuri, Karlsson, Annika C, and Betts, Michael R

Subjects
Lymphoid Tissue, Lymph Nodes, CD4-Positive T-Lymphocytes, Humans, HIV-1, HIV Infections, Viral Load, Case-Control Studies, Immunologic Surveillance, Virology, Microbiology, Immunology, Medical Microbiology
Abstract

CD4+ T cells subsets have a wide range of important helper and regulatory functions in the immune system. Several studies have specifically suggested that circulating effector CD4+ T cells may play a direct role in control of HIV replication through cytolytic activity or autocrine β-chemokine production. However, it remains unclear whether effector CD4+ T cells expressing cytolytic molecules and β-chemokines are present within lymph nodes (LNs), a major site of HIV replication. Here, we report that expression of β-chemokines and cytolytic molecules are enriched within a CD4+ T cell population with high levels of the T-box transcription factors T-bet and eomesodermin (Eomes). This effector population is predominately found in peripheral blood and is limited in LNs regardless of HIV infection or treatment status. As a result, CD4+ T cells generally lack effector functions in LNs, including cytolytic capacity and IFNγ and β-chemokine expression, even in HIV elite controllers and during acute/early HIV infection. While we do find the presence of degranulating CD4+ T cells in LNs, these cells do not bear functional or transcriptional effector T cell properties and are inherently poor to form stable immunological synapses compared to their peripheral blood counterparts. We demonstrate that CD4+ T cell cytolytic function, phenotype, and programming in the peripheral blood is dissociated from those characteristics found in lymphoid tissues. Together, these data challenge our current models based on blood and suggest spatially and temporally dissociated mechanisms of viral control in lymphoid tissues.

Published
2018

38. TET2 regulates early and late transitions in exhausted CD8+T-cell differentiation and limits CAR T-cell function

Author

Dimitri, Alexander J, primary, Baxter, Amy E, additional, Chen, Gregory M, additional, Hopkins, Caitlin R, additional, Rouin, Geoffrey T, additional, Huang, Hua, additional, Kong, Weimin, additional, Holliday, Christopher H, additional, Wiebking, Volker, additional, Bartoszek, Robert, additional, Drury, Sydney, additional, Dalton, Katherine, additional, Koucky, Owen M, additional, Chen, Zeyu, additional, Giles, Josephine R, additional, Jung, In-Young, additional, O'Connor, Roddy, additional, Collins, Sierra, additional, Everett, John K, additional, Amses, Kevin, additional, Sherrill-Mix, Scott, additional, Chandra, Aditi, additional, Goldman, Naomi, additional, Vahedi, Golnaz, additional, Jadlowsky, Julie K, additional, Young, Regina M, additional, Melenhorst, Jan Joseph, additional, Maude, Shannon L, additional, Levine, Bruce L, additional, Frey, Noelle V, additional, Berger, Shelley L, additional, Grupp, Stephan A, additional, Porter, David L, additional, Herbst, Friederike, additional, Porteus, Matthew H, additional, Bushman, Frederic D, additional, Weber, Evan W, additional, Wherry, E. John, additional, Jordan, Martha S, additional, and Fraietta, Joseph A, additional

Published
2024
Full Text
View/download PDF

39. Immunologic Predictors of Vaccine Responsiveness in Patients With Lymphoma and Chronic Lymphocytic Leukemia

Author

Chong, Elise A, primary, Kumashie, Kingsley Gideon, additional, Chong, Emeline R, additional, Fabrizio, Joseph, additional, Gupta, Aditi, additional, Svoboda, Jakub, additional, Barta, Stefan K, additional, Walsh, Kristy M, additional, Napier, Ellen B, additional, Lundberg, Rachel K, additional, Nasta, Sunita D, additional, Gerson, James N, additional, Landsburg, Daniel J, additional, Gonzalez, Joyce, additional, Gaano, Andrew, additional, Weirick, Madison E, additional, McAllister, Christopher M, additional, Awofolaju, Moses, additional, John, Gavin N, additional, Kammerman, Shane C, additional, Novacek, Josef, additional, Pajarillo, Raymone, additional, Lundgreen, Kendall A, additional, Tanenbaum, Nicole, additional, Gouma, Sigrid, additional, Drapeau, Elizabeth M, additional, Adamski, Sharon, additional, D’Andrea, Kurt, additional, Pattekar, Ajinkya, additional, Hicks, Amanda, additional, Korte, Scott, additional, Sharma, Harsh, additional, Herring, Sarah, additional, Williams, Justine C, additional, Hamilton, Jacob T, additional, Bates, Paul, additional, Hensley, Scott E, additional, Luning Prak, Eline T, additional, Greenplate, Allison R, additional, Wherry, E John, additional, Schuster, Stephen J, additional, Ruella, Marco, additional, and Vella, Laura A, additional

Published
2024
Full Text
View/download PDF

40. Single-cell Masked Autoencoder: An Accurate and Interpretable Automated Immunophenotyper

Author

Kim, Jaesik, primary, Ionita, Matei, additional, Lee, Matthew, additional, McKeague, Michelle L., additional, Pattekar, Ajinkya, additional, Painter, Mark M., additional, Wagenaar, Joost, additional, Truong, Van, additional, Norton, Dylan T., additional, Mathew, Divij, additional, Nam, Yonghyun, additional, Apostolidis, Sokratis A., additional, Clendenin, Cynthia, additional, Orzechowski, Patryk, additional, Jung, Sang-Hyuk, additional, Woerner, Jakob, additional, Ittner, Caroline A.G., additional, Turner, Alexandra P., additional, Esperanza, Mika, additional, Dunn, Thomas G., additional, Mangalmurti, Nilam S., additional, Reilly, John P., additional, Meyer, Nuala J., additional, Calfee, Carolyn S., additional, Liu, Kathleen D., additional, Matthy, Michael A., additional, Swigart, Lamorna Brown, additional, Burnham, Ellen L., additional, McKeehan, Jeffrey, additional, Gandotra, Sheetal, additional, Russel, Derek W., additional, Gibbs, Kevin W., additional, Thomas, Karl W., additional, Barot, Harsh, additional, Greenplate, Allison R., additional, Wherry, E. John, additional, and Kim, Dokyoon, additional

Published
2024
Full Text
View/download PDF

41. Data from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

Author

Byrne, Katelyn T., primary, Betts, Courtney B., primary, Mick, Rosemarie, primary, Sivagnanam, Shamilene, primary, Bajor, David L., primary, Laheru, Daniel A., primary, Chiorean, E. Gabriela, primary, O'Hara, Mark H., primary, Liudahl, Shannon M., primary, Newcomb, Craig, primary, Alanio, Cécile, primary, Ferreira, Ana P., primary, Park, Byung S., primary, Ohtani, Takuya, primary, Huffman, Austin P., primary, Väyrynen, Sara A., primary, Dias Costa, Andressa, primary, Kaiser, Judith C., primary, Lacroix, Andreanne M., primary, Redlinger, Colleen, primary, Stern, Martin, primary, Nowak, Jonathan A., primary, Wherry, E. John, primary, Cheever, Martin A., primary, Wolpin, Brian M., primary, Furth, Emma E., primary, Jaffee, Elizabeth M., primary, Coussens, Lisa M., primary, and Vonderheide, Robert H., primary

Published
2024
Full Text
View/download PDF

42. Supplementary Table 2 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

Author

Byrne, Katelyn T., primary, Betts, Courtney B., primary, Mick, Rosemarie, primary, Sivagnanam, Shamilene, primary, Bajor, David L., primary, Laheru, Daniel A., primary, Chiorean, E. Gabriela, primary, O'Hara, Mark H., primary, Liudahl, Shannon M., primary, Newcomb, Craig, primary, Alanio, Cécile, primary, Ferreira, Ana P., primary, Park, Byung S., primary, Ohtani, Takuya, primary, Huffman, Austin P., primary, Väyrynen, Sara A., primary, Dias Costa, Andressa, primary, Kaiser, Judith C., primary, Lacroix, Andreanne M., primary, Redlinger, Colleen, primary, Stern, Martin, primary, Nowak, Jonathan A., primary, Wherry, E. John, primary, Cheever, Martin A., primary, Wolpin, Brian M., primary, Furth, Emma E., primary, Jaffee, Elizabeth M., primary, Coussens, Lisa M., primary, and Vonderheide, Robert H., primary

Published
2024
Full Text
View/download PDF

43. Supplementary Figure 1 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

Author

Byrne, Katelyn T., primary, Betts, Courtney B., primary, Mick, Rosemarie, primary, Sivagnanam, Shamilene, primary, Bajor, David L., primary, Laheru, Daniel A., primary, Chiorean, E. Gabriela, primary, O'Hara, Mark H., primary, Liudahl, Shannon M., primary, Newcomb, Craig, primary, Alanio, Cécile, primary, Ferreira, Ana P., primary, Park, Byung S., primary, Ohtani, Takuya, primary, Huffman, Austin P., primary, Väyrynen, Sara A., primary, Dias Costa, Andressa, primary, Kaiser, Judith C., primary, Lacroix, Andreanne M., primary, Redlinger, Colleen, primary, Stern, Martin, primary, Nowak, Jonathan A., primary, Wherry, E. John, primary, Cheever, Martin A., primary, Wolpin, Brian M., primary, Furth, Emma E., primary, Jaffee, Elizabeth M., primary, Coussens, Lisa M., primary, and Vonderheide, Robert H., primary

Published
2024
Full Text
View/download PDF

44. Supplementary Figure 2 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

Author

Byrne, Katelyn T., primary, Betts, Courtney B., primary, Mick, Rosemarie, primary, Sivagnanam, Shamilene, primary, Bajor, David L., primary, Laheru, Daniel A., primary, Chiorean, E. Gabriela, primary, O'Hara, Mark H., primary, Liudahl, Shannon M., primary, Newcomb, Craig, primary, Alanio, Cécile, primary, Ferreira, Ana P., primary, Park, Byung S., primary, Ohtani, Takuya, primary, Huffman, Austin P., primary, Väyrynen, Sara A., primary, Dias Costa, Andressa, primary, Kaiser, Judith C., primary, Lacroix, Andreanne M., primary, Redlinger, Colleen, primary, Stern, Martin, primary, Nowak, Jonathan A., primary, Wherry, E. John, primary, Cheever, Martin A., primary, Wolpin, Brian M., primary, Furth, Emma E., primary, Jaffee, Elizabeth M., primary, Coussens, Lisa M., primary, and Vonderheide, Robert H., primary

Published
2024
Full Text
View/download PDF

45. Supplementary Table 3 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

Author

Byrne, Katelyn T., primary, Betts, Courtney B., primary, Mick, Rosemarie, primary, Sivagnanam, Shamilene, primary, Bajor, David L., primary, Laheru, Daniel A., primary, Chiorean, E. Gabriela, primary, O'Hara, Mark H., primary, Liudahl, Shannon M., primary, Newcomb, Craig, primary, Alanio, Cécile, primary, Ferreira, Ana P., primary, Park, Byung S., primary, Ohtani, Takuya, primary, Huffman, Austin P., primary, Väyrynen, Sara A., primary, Dias Costa, Andressa, primary, Kaiser, Judith C., primary, Lacroix, Andreanne M., primary, Redlinger, Colleen, primary, Stern, Martin, primary, Nowak, Jonathan A., primary, Wherry, E. John, primary, Cheever, Martin A., primary, Wolpin, Brian M., primary, Furth, Emma E., primary, Jaffee, Elizabeth M., primary, Coussens, Lisa M., primary, and Vonderheide, Robert H., primary

Published
2024
Full Text
View/download PDF

46. Supplementary Figure 3 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

Author

Byrne, Katelyn T., primary, Betts, Courtney B., primary, Mick, Rosemarie, primary, Sivagnanam, Shamilene, primary, Bajor, David L., primary, Laheru, Daniel A., primary, Chiorean, E. Gabriela, primary, O'Hara, Mark H., primary, Liudahl, Shannon M., primary, Newcomb, Craig, primary, Alanio, Cécile, primary, Ferreira, Ana P., primary, Park, Byung S., primary, Ohtani, Takuya, primary, Huffman, Austin P., primary, Väyrynen, Sara A., primary, Dias Costa, Andressa, primary, Kaiser, Judith C., primary, Lacroix, Andreanne M., primary, Redlinger, Colleen, primary, Stern, Martin, primary, Nowak, Jonathan A., primary, Wherry, E. John, primary, Cheever, Martin A., primary, Wolpin, Brian M., primary, Furth, Emma E., primary, Jaffee, Elizabeth M., primary, Coussens, Lisa M., primary, and Vonderheide, Robert H., primary

Published
2024
Full Text
View/download PDF

47. Supplementary Table 4 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

Author

Byrne, Katelyn T., primary, Betts, Courtney B., primary, Mick, Rosemarie, primary, Sivagnanam, Shamilene, primary, Bajor, David L., primary, Laheru, Daniel A., primary, Chiorean, E. Gabriela, primary, O'Hara, Mark H., primary, Liudahl, Shannon M., primary, Newcomb, Craig, primary, Alanio, Cécile, primary, Ferreira, Ana P., primary, Park, Byung S., primary, Ohtani, Takuya, primary, Huffman, Austin P., primary, Väyrynen, Sara A., primary, Dias Costa, Andressa, primary, Kaiser, Judith C., primary, Lacroix, Andreanne M., primary, Redlinger, Colleen, primary, Stern, Martin, primary, Nowak, Jonathan A., primary, Wherry, E. John, primary, Cheever, Martin A., primary, Wolpin, Brian M., primary, Furth, Emma E., primary, Jaffee, Elizabeth M., primary, Coussens, Lisa M., primary, and Vonderheide, Robert H., primary

Published
2024
Full Text
View/download PDF

48. Supplementary Table 1 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

Author

Byrne, Katelyn T., primary, Betts, Courtney B., primary, Mick, Rosemarie, primary, Sivagnanam, Shamilene, primary, Bajor, David L., primary, Laheru, Daniel A., primary, Chiorean, E. Gabriela, primary, O'Hara, Mark H., primary, Liudahl, Shannon M., primary, Newcomb, Craig, primary, Alanio, Cécile, primary, Ferreira, Ana P., primary, Park, Byung S., primary, Ohtani, Takuya, primary, Huffman, Austin P., primary, Väyrynen, Sara A., primary, Dias Costa, Andressa, primary, Kaiser, Judith C., primary, Lacroix, Andreanne M., primary, Redlinger, Colleen, primary, Stern, Martin, primary, Nowak, Jonathan A., primary, Wherry, E. John, primary, Cheever, Martin A., primary, Wolpin, Brian M., primary, Furth, Emma E., primary, Jaffee, Elizabeth M., primary, Coussens, Lisa M., primary, and Vonderheide, Robert H., primary

Published
2024
Full Text
View/download PDF

49. Supplementary Figure 4 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

Author

Byrne, Katelyn T., primary, Betts, Courtney B., primary, Mick, Rosemarie, primary, Sivagnanam, Shamilene, primary, Bajor, David L., primary, Laheru, Daniel A., primary, Chiorean, E. Gabriela, primary, O'Hara, Mark H., primary, Liudahl, Shannon M., primary, Newcomb, Craig, primary, Alanio, Cécile, primary, Ferreira, Ana P., primary, Park, Byung S., primary, Ohtani, Takuya, primary, Huffman, Austin P., primary, Väyrynen, Sara A., primary, Dias Costa, Andressa, primary, Kaiser, Judith C., primary, Lacroix, Andreanne M., primary, Redlinger, Colleen, primary, Stern, Martin, primary, Nowak, Jonathan A., primary, Wherry, E. John, primary, Cheever, Martin A., primary, Wolpin, Brian M., primary, Furth, Emma E., primary, Jaffee, Elizabeth M., primary, Coussens, Lisa M., primary, and Vonderheide, Robert H., primary

Published
2024
Full Text
View/download PDF

50. FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma

Author

Anderson, Thomas M., primary, Chang, Bryan H., additional, Huang, Alexander C., additional, Xu, Xiaowei, additional, Yoon, Daniel, additional, Shang, Catherine G., additional, Mick, Rosemarie, additional, Schubert, Erin, additional, McGettigan, Suzanne, additional, Kreider, Kristin, additional, Xu, Wei, additional, Wherry, E. John, additional, Schuchter, Lynn M., additional, Amaravadi, Ravi K., additional, Mitchell, Tara C., additional, and Farwell, Michael D., additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results